CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCD) FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS: INITIAL RESULTS OF A MULTICENTER, OPEN LABEL PHASE II STUDY

被引：0
|
作者：
Bringhen, S. [1 ]
Federica, C. [1 ]
Petrucci, M. [2 ]
Gay, F. [1 ]
Federico, V. [2 ]
Conticello, C. [2 ]
Pantani, L. [2 ]
Montefusco, V. [2 ]
Benevolo, G. [2 ]
Aschero, S. [1 ]
Offidani, M. [2 ]
Villani, O. [2 ]
Siniscalchi, A. [2 ]
Rossi, D. [2 ]
Magarotto, V. [1 ]
Sonneveld, P. [3 ]
Boccadoro, M. [1 ]
Palumbo, A. [1 ]
机构：
[1] Univ Torino, Div Hematol, Myeloma Unit, Turin, Italy
[2] GIMEMA, Italian Multiple Myeloma Network, Rome, Italy
[3] Erasmus MC, Dept Hematol, Rotterdam, Netherlands
来源：
HAEMATOLOGICA | 2013年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S578
引用
收藏
页码：242 / 242
页数：1
相关论文
共 50 条
  • [41] AN OPEN-LABEL, PHASE 2 STUDY TO EVALUATE THE ORAL COMBINATION OF IXAZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Dimopoulos, M. A.
    Grosicki, S.
    Jedrzejczak, W.
    Nahi, H.
    Gruber, A.
    Hansson, M.
    Byrne, C.
    Labotka, R.
    Teng, Z.
    Yang, H.
    Grzasko, N.
    Kumar, S.
    HAEMATOLOGICA, 2017, 102 : 111 - 111
  • [42] WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (WKCYD) FOLLOWED BY MAINTENANCE WITH WEEKLY CARFILZOMIB (WK) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
    Bringhen, S.
    De Paoli, L.
    Larocca, A.
    Ballanti, S.
    Gentilini, F.
    Liberati, A. M.
    Passera, R.
    Bernardini, A.
    Esma, F.
    Galieni, P.
    Offidani, M.
    Corradini, P.
    Gaidano, G.
    Boccadoro, M.
    Sonneveld, P.
    Palumbo, A.
    HAEMATOLOGICA, 2016, 101 : 2 - 2
  • [43] Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
    S Bringhen
    M D'Agostino
    L De Paoli
    V Montefusco
    A M Liberati
    P Galieni
    S Grammatico
    V E Muccio
    F Esma
    C De Angelis
    P Musto
    S Ballanti
    M Offidani
    M T Petrucci
    G Gaidano
    P Corradini
    A Palumbo
    P Sonneveld
    M Boccadoro
    Leukemia, 2018, 32 : 979 - 985
  • [44] Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
    Dimopoulos, Meletios
    Quach, Hang
    Mateos, Maria-Victoria
    Landgren, Ola
    Leleu, Xavier
    Siegel, David
    Weisel, Katja
    Yang, Hui
    Klippel, Zandra
    Zahlten-Kumeli, Anita
    Usmani, Saad Z.
    LANCET, 2020, 396 (10245): : 186 - 197
  • [45] Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM)
    Jagannath, Sundar
    Vij, Ravi
    Stewart, A. Keith
    Somlo, George
    Jakubowiak, Andrzej
    Reiman, Tony
    Trudel, Suzanne
    Taylor, Jessica
    Fuhrman, Diana
    Cruickshank, Scott
    Schwartz, Richard
    Kunkel, Lori
    Siegel, David
    BLOOD, 2008, 112 (11) : 319 - 319
  • [46] Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study
    Jian, Yuan
    Chang, Long
    Shi, Mingxia
    Sun, Ying
    Chu, Xiaoxia
    Xue, Hua
    Huang, Wenrong
    Shen, Xuliang
    Ma, Jie
    Jia, Guorong
    Peng, Yaqing
    Xi, Zhenfang
    Zhao, Yanhong
    Ma, Yanping
    Xiao, Jing
    Ma, Guangyu
    Wang, Qingming
    Bao, Li
    Dong, Yujun
    Zhou, Hebing
    Sun, Chunyan
    Su, Guohong
    Yan, Yan
    Qimuge, Saiyin
    Su, Liping
    Sun, Jingnan
    Tian, Weiwei
    Sun, Xiuli
    Jing, Hongmei
    Gao, Da
    Chen, Wenming
    Li, Jian
    Gao, Wen
    BLOOD, 2022, 140 : 10167 - 10169
  • [47] Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study
    Stewart, A. Keith
    Rajkumar, S. Vincent
    Dimopoulos, Meletios A.
    Masszi, Tamas
    Spicka, Ivan
    Oriol, Albert
    Hajek, Roman
    Rosinol, Laura
    Siegel, David S.
    Mihaylov, Georgi G.
    Goranova-Marinova, Veselina
    Rajnics, Peter
    Suvorov, Aleksandr
    Niesvizky, Ruben
    Jakubowiak, Andrzej
    San Miguel, Jesus F.
    Ludwig, Heinz
    Zojwalla, Naseem
    Tonda, Margaret E.
    Xing, Biao
    Moreau, Philippe
    Palumbo, Antonio
    BLOOD, 2014, 124 (21)
  • [48] Interim results from ASPIRE, a randomized, open-label, multicenter phase 3 study evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma
    Stewart, A. K.
    Rajkumar, S. V.
    Dimopoulos, M. A.
    Mihaylov, G. G.
    Goranova-Marinova, V.
    Rajnics, P.
    Suvorov, A.
    Jakubowiak, A. J.
    San-Miguel, J. F.
    Zojwalla, N.
    Moreau, P.
    Palumbo, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 20 - 20
  • [49] Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
    Sonneveld, Pieter
    Asselbergs, Emilie
    Zweegman, Sonja
    van der Holt, Bronno
    Kersten, Marie Jose
    Vellenga, Edo
    van Marwijk-Kooy, Marinus
    Broyl, Annemiek
    de Weerdt, Okke
    Lonergan, Sarah
    Palumbo, Antonio
    Lokhorstl, Henk
    BLOOD, 2015, 125 (03) : 449 - 456
  • [50] Phase II trial of lenalidomide, cyclophosphamide, and dexamethasone (CRd) for newly diagnosed myeloma
    Kumar, Shaji
    Hayman, Suzanne R.
    Buadi, Francis K.
    Lacy, Martha Q.
    Stewart, Keith
    Greipp, Philip R.
    Russell, Stephen
    Zeldenrust, Steven
    Gertz, Morie A.
    Bergsagel, Leif
    Fonseca, Rafael
    Allred, Jacob
    Campbell, Megan
    Lust, John A.
    Witzig, Thomas E.
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Dispenzieri, Angela
    BLOOD, 2007, 110 (11) : 64A - 64A
12345